search
Back to results

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (ACTION3)

Primary Purpose

FSGS

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
DMX-200
Placebo
Sponsored by
Dimerix Bioscience Pty Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for FSGS

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients must be 18 to 80 years old
  2. A diagnosis of FSGS confirmed by kidney biopsy or documentation of a genetic mutation in a podocyte protein associated with FSGS
  3. Must be either receiving an ARB at the maximal tolerated dose or willing to transition
  4. If taking corticosteroids, the dosage must be stable for ≥4 weeks prior to Screening and during Stablization
  5. If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, or sodium-glucose co-transporter-2 (SGLT2) inhibitors, the dose and regimen must be stable for ≥12 weeks prior to Screening and during Stablization
  6. Urine PCR >1.5 g/g (>169.5 mg/mmol) or 24-hour total protein >1.5 g/day based on 24-hour urine collection during Screening.
  7. Estimated GFR ≥25 mL/min/1.73 m2 at Screening
  8. Seated blood pressure ≤160/100 mm Hg (mean of 3 values) at Screening
  9. Body mass index ≤40 kg/m2 at Screening.
  10. A female patient is eligible to participate if she is not pregnant or planning to become pregnant during the study, not breastfeeding, and at least one of the following conditions applies:

    1. Is not of childbearing potential
    2. If of childbearing potential and agrees to use a highly effective method of contraception consistently during the treatment period
  11. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception

Exclusion Criteria:

  1. Has FSGS secondary to another condition.
  2. History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as glycated hemoglobin [HbA1c] >8%)
  3. History of lymphoma, leukemia, or any active malignancy within the past 2 years
  4. Active clinically significant hepatobiliary disease.
  5. Documented history of heart failure (New York Heart Association Class III/IV) or a major adverse cardiac event within 12 weeks prior to Screening.
  6. Has a physical, medical, or psychological condition, that in the opinion of the Investigator, may interfere with the evaluation the study.
  7. The patient has a history of alcohol or illicit drug use disorder within 1 year prior to Screening.
  8. Had a prior organ transplant or stem cell transplant, with the exception of corneal transplant.
  9. Positive screening assessment for viral hepatitis B surface antigen, or anti-hepatitis C virus antibody AND positive HCV RNA, or human immunodeficiency virus 1 and 2.
  10. Serum potassium levels >5.5 mmol/L at Screening.
  11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2 × upper limit of normal (ULN) at Screening
  12. Treatment with immunosuppressant biological drugs, calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 12 weeks prior to Screening.
  13. History of serious side effects or allergic response to an angiotensin II antagonist or has a known sensitivity to any components in the Investigational Product.
  14. Prior participation in any Dimerix-sponsored DMX-200 clinical study.
  15. Participation in a clinical study with an Investigational Product within 28 days or 5 half-lives (whichever is longer) prior to Screening or plans to participate in another study during the course of this study.
  16. Are study site personnel directly affiliated with this study and their immediate families.

Sites / Locations

  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 10Recruiting
  • ACTION3 Investigational Site 13Recruiting
  • ACTION3 Investigational Site 20Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 11
  • ACTION3 Investigational Site 15Recruiting
  • ACTION 3 Investigator Site 19Recruiting
  • ACTION3 Investigational Site 8Recruiting
  • ACTION3 Investigational Site 21Recruiting
  • ACTION3 Investigational Site 18Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 17Recruiting
  • ACTION3 Investigational Site 12Recruiting
  • ACTION3 Investigational Site 9Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 14Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 16Recruiting
  • ACTION3 Investigational Site 7Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • Action3 Investigator Site 6Recruiting
  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 7Recruiting
  • Action3 Investigator Site 3Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 7Recruiting
  • ACTION3 Investigational Site 6Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 3
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 7Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 8Recruiting
  • ACTION3 Investigational Site 9Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 4Recruiting
  • ACTION3 Investigational Site 6Recruiting
  • ACTION3 Investigational Site 1Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 3Recruiting
  • ACTION3 Investigational Site 6Recruiting
  • ACTION3 Investigational Site 5Recruiting
  • ACTION3 Investigational Site 2Recruiting
  • ACTION3 Investigational Site 1Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

DMX-200 (repagermanium)

Placebo

Arm Description

Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks)

Patients will receive 120 mg immediate release capsules of Placebo twice daily

Outcomes

Primary Outcome Measures

Evaluate the efficacy of DMX-200 in terms of urine PCR in patients with FSGS who are receiving an ARB
Percent change in urine PCR (based on 24-hour urine collection)
Evaluate the efficacy of DMX-200 in terms of eGFR slope in patients with FSGS who are receiving an ARB (Analysis at week 35 and Week 104)
Slope of eGFR

Secondary Outcome Measures

Evaluate the incidence and severity of AEs with treatment of DMX-200 in patients with FSGS who are receiving an ARB
Incidence and severity of AEs and clinically significant changes following treatment with DMX-200 compared with placebo
Evaluate the effect of DMX-200 on kidney function parameters as defined by the onset of kidney failure, a 30% decline in eGFR from Baseline, or death from kidney or cardiovascular causes in patients with FSGS who are receiving an ARB
Patients on treatment with DMX-200 compared with placebo that meet a composite endpoint of worsening in kidney function

Full Information

First Posted
November 29, 2021
Last Updated
December 27, 2022
Sponsor
Dimerix Bioscience Pty Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05183646
Brief Title
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Acronym
ACTION3
Official Title
A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 30, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dimerix Bioscience Pty Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB.
Detailed Description
This is a pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS. The total study duration per patient is estimated to be maximum of 122 weeks, a Screening and Qualification period of between 6 and 14 weeks (including a 4 week period to complete the assessments required for Screening (Visit 1), a Titration (if required, up to 4 weeks) and, a 6-weeks of Stabilization, a 104-week Treatment period, and up to a 4-week off-treatment Follow up period. This is a hybrid virtual study which will utilize a decentralized model, ie, using a combination of on-site visits and optional remote visits

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
FSGS

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double blind study
Allocation
Randomized
Enrollment
286 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DMX-200 (repagermanium)
Arm Type
Experimental
Arm Description
Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients will receive 120 mg immediate release capsules of Placebo twice daily
Intervention Type
Drug
Intervention Name(s)
DMX-200
Other Intervention Name(s)
Repagermanium
Intervention Description
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Patients will receive 120 mg capsules of Placebo twice daily
Primary Outcome Measure Information:
Title
Evaluate the efficacy of DMX-200 in terms of urine PCR in patients with FSGS who are receiving an ARB
Description
Percent change in urine PCR (based on 24-hour urine collection)
Time Frame
Baseline to Week 35
Title
Evaluate the efficacy of DMX-200 in terms of eGFR slope in patients with FSGS who are receiving an ARB (Analysis at week 35 and Week 104)
Description
Slope of eGFR
Time Frame
Baseline to Week 104
Secondary Outcome Measure Information:
Title
Evaluate the incidence and severity of AEs with treatment of DMX-200 in patients with FSGS who are receiving an ARB
Description
Incidence and severity of AEs and clinically significant changes following treatment with DMX-200 compared with placebo
Time Frame
Baseline to Week 104
Title
Evaluate the effect of DMX-200 on kidney function parameters as defined by the onset of kidney failure, a 30% decline in eGFR from Baseline, or death from kidney or cardiovascular causes in patients with FSGS who are receiving an ARB
Description
Patients on treatment with DMX-200 compared with placebo that meet a composite endpoint of worsening in kidney function
Time Frame
Baseline to Week 104

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must be 18 to 80 years old A diagnosis of FSGS confirmed by kidney biopsy or documentation of a genetic mutation in a podocyte protein associated with FSGS Must be either receiving an ARB at the maximal tolerated dose or willing to transition If taking corticosteroids, the dosage must be stable for ≥4 weeks prior to Screening and during Stablization If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, or sodium-glucose co-transporter-2 (SGLT2) inhibitors, the dose and regimen must be stable for ≥12 weeks prior to Screening and during Stablization Urine PCR >1.5 g/g (>169.5 mg/mmol) or 24-hour total protein >1.5 g/day based on 24-hour urine collection during Screening. Estimated GFR ≥25 mL/min/1.73 m2 at Screening Seated blood pressure ≤160/100 mm Hg (mean of 3 values) at Screening Body mass index ≤40 kg/m2 at Screening. A female patient is eligible to participate if she is not pregnant or planning to become pregnant during the study, not breastfeeding, and at least one of the following conditions applies: Is not of childbearing potential If of childbearing potential and agrees to use a highly effective method of contraception consistently during the treatment period A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception Exclusion Criteria: Has FSGS secondary to another condition. History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as glycated hemoglobin [HbA1c] >8%) History of lymphoma, leukemia, or any active malignancy within the past 2 years Active clinically significant hepatobiliary disease. Documented history of heart failure (New York Heart Association Class III/IV) or a major adverse cardiac event within 12 weeks prior to Screening. Has a physical, medical, or psychological condition, that in the opinion of the Investigator, may interfere with the evaluation the study. The patient has a history of alcohol or illicit drug use disorder within 1 year prior to Screening. Had a prior organ transplant or stem cell transplant, with the exception of corneal transplant. Positive screening assessment for viral hepatitis B surface antigen, or anti-hepatitis C virus antibody AND positive HCV RNA, or human immunodeficiency virus 1 and 2. Serum potassium levels >5.5 mmol/L at Screening. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2 × upper limit of normal (ULN) at Screening Treatment with immunosuppressant biological drugs, calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 12 weeks prior to Screening. History of serious side effects or allergic response to an angiotensin II antagonist or has a known sensitivity to any components in the Investigational Product. Prior participation in any Dimerix-sponsored DMX-200 clinical study. Participation in a clinical study with an Investigational Product within 28 days or 5 half-lives (whichever is longer) prior to Screening or plans to participate in another study during the course of this study. Are study site personnel directly affiliated with this study and their immediate families.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ash Soman
Phone
1300 813 321
Email
ACTION3@dimerix.com
First Name & Middle Initial & Last Name or Official Title & Degree
Alisha Smith
Phone
1300 813 321
Email
ACTION3@dimerix.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ash Soman
Organizational Affiliation
Dimerix Bioscience Pty Ltd
Official's Role
Study Director
Facility Information:
Facility Name
ACTION3 Investigational Site 4
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85027
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 10
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 13
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 20
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Coral Springs
State/Province
Florida
ZIP/Postal Code
33071
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 11
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
ACTION3 Investigational Site 15
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION 3 Investigator Site 19
City
Oak Brook
State/Province
Illinois
ZIP/Postal Code
60523
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 8
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 21
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01107
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 18
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 17
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68510
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 12
City
Roseburg
State/Province
Oregon
ZIP/Postal Code
97471
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 9
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29306
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 14
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 16
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 7
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84115
Country
United States
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Buenos Aires
Country
Argentina
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Ciudad Autonoma Buenos Aires
Country
Argentina
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 4
City
Ciudad Autonoma Buenos Aires
Country
Argentina
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Córdoba
Country
Argentina
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Santa Fe
Country
Argentina
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Brisbane
Country
Australia
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Melbourne
Country
Australia
Individual Site Status
Recruiting
Facility Name
Action3 Investigator Site 6
City
Melbourne
Country
Australia
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 4
City
Sydney
Country
Australia
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Sydney
Country
Australia
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 7
City
Sydney
Country
Australia
Individual Site Status
Recruiting
Facility Name
Action3 Investigator Site 3
City
Sydney
Country
Australia
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Botucatu
Country
Brazil
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 4
City
Recife
Country
Brazil
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Rio De Janeiro
Country
Brazil
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
São Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
São Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Copenhagen
Country
Denmark
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Kolding
Country
Denmark
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Odense
Country
Denmark
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 4
City
Bordeaux
State/Province
Gironde
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Créteil
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Grenoble
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Marseille
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 7
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 6
City
Saint-Priest-en-Jarez
Country
France
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Hong Kong
Country
Hong Kong
Individual Site Status
Not yet recruiting
Facility Name
ACTION3 Investigational Site 1
City
Auckland
ZIP/Postal Code
1023
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Hamilton
ZIP/Postal Code
3204
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 7
City
Córdoba
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 8
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 9
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Sevilla
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 4
City
Sevilla
Country
Spain
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
New Taipei City
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 4
City
New Taipei City
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 6
City
Taichung
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Taipei CITY
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 3
City
Carshalton
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 6
City
Glasgow
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 5
City
Leicester
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 2
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
ACTION3 Investigational Site 1
City
Salford
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

We'll reach out to this number within 24 hrs